Monoclonal antibodies (RQ33, RQ40, RQ41, RQ43) with broad neutralization potency against SARS-CoV-2 variants including Omicron lineages BA.1, BA.1.1, BA.2, Delta, and D614G.

Patentradars sammanfattning

This patent discloses a panel of anti-SARS-CoV-2 monoclonal antibodies (mAbs) engineered in a YTE-TM backbone, demonstrating broad-spectrum pseudovirus neutralization across multiple variants. Antibodies RQ40, RQ41, and RQ43 achieve highest potency (EC50 <20 ng/mL) against Omicron BA.1, BA.1.1, BA.2, and D614G, meeting or exceeding the target product profile (TPP) threshold of <100 ng/mL across Omicron lineages. RQ33 shows high potency against BA.1 and BA.1.1 but reduced activity against BA.2 and Delta. The YTE-TM Fc-engineering modification is intended to extend half-life and enhance effector function.

AI-genererad och redaktionellt processad.